NL-OMON36627已完成不适用
A Phase I, multi-center, open label, dose escalation study of LEQ506, an oral Smoothened inhibitor, in patients with advanced solid tumors - Phase I study with LEQ506, an oral smoothened inhibitor
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Dose escalation phase: patients with a with a histologically or cytologically confirmed solid tumor, who have progressed despite standard therapy or for which no standard therapy exists. Patients with recurrent or refractory Medullo Blastoma (MB) and patients with metastatic or locally advanced Basel Cell Carcinoma (BCC) that cannot be with local therapy.
- •- Expansion phase: patients with tumors that are characterized by Hedgehog pathway activation, such as recurrent or refractory MB or metastatic or locally advanced BCC
- •- WHO performance status *2.
- •- Required baseline laboratory values:
- •*Absolute Neutrophil Count *1.5x109/L
- •*Hemoglobin * 9 g/dl <= 5.58 mmol/l
- •*Platelets * 80x109/L
- •*AST/SGOT and ALT/SGPT * 2.5 x Upper Limit of Normal (ULN) or * 5.0 x ULN if liver metastases are present
- •*Serum bilirubin * 1.5 x ULN
- •*Serum creatinine * 1.5 x ULN or 24-hour clearance * 50 ml/min.
- •- Patients must have fully recovered from the effects of prior major surgery and from any acute toxic effects of prior chemotherapy and radiotherapy.
- •- A negative serum pregnancy test * 72 hours before starting study treatment
排除标准
- •- History of primary central nervous system tumors or symptomatic brain metastases (except recurrent MB). However, patients with resected brain metastasis with no radiological evidence of disease or with stable brain metastasis with no evidence of progression are eligible. Such patients must have no need for treatment with steroids or anti-epileptic medications.
- •- Known diagnosis of HIV or Hepatitis C
- •- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the
- •absorption of LEQ506
- •- Any unresolved nausea, vomiting, or diarrhea CTCAE grade >1.
- •- Impaired cardiac function or clinically significant cardiac diseases, including any of the
- •1) Acute myocardial infarction or angina pectoris * 3 months prior to starting study drug
- •2) QTcF > 450 msec for males and > 470 msec for females on screening ECG
- •3) Medical history of clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension)
- •- Any other concurrent severe and/or uncontrolled concomitant medical condition (e.g. uncontrolled diabetes, clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection).
- •- Systemic anti-cancer treatment or radiotherapy < 2 weeks before the first dose of study treatment
- •(* 4 weeks for monoclonal antibodies).
- •- Prior treatment with investigational agents * 4 weeks or * 5 x their half-lives (whichever is longer) before the first dose of study treatment.
- •- Treatment with medications that are known to be strong inhibitors or inducers of CYP3A4/5
- •- Treatment with medications that are known to be substrates of CYP3A4/5 or CYP2C9 and that have low therapeutic indices.
研究者
相似试验
终止
1 期
Intravenous APG-1387 administered to patients with advanced solid tumors and lymphomas to test for safety, tolerability and effect of APG-1387 on the body and how APG-1387 is processed by the human bodyadvanced solid tumorCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaCancer - Any cancerlymphomaACTRN12614000268640Jiangsu Ascentage Pharma Inc30
已完成
不适用
A phase I, open-label, multi-center, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignanciesAdvanced and/or metastatic cancer10027655NL-OMON45230ovartis13
已完成
不适用
A phase I, open label, multicenter, dose-escalation study of oral HDM201 in adult patients with advanced solid and hematological tumors characterized by wild-type TP53Solid and hematologic tumors1002432410027655NL-OMON46915ovartis24
已完成
不适用
A multicenter, open label, phase 1 dose escalation study to evaluate the pharmacokinetics, safety, and tolerability of INC280 tablet formulation with food in patients with cMET dysregulated advanced solid tumorsNL-OMON43009ovartis3
进行中（未招募）
1 期
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)EUCTR2019-002666-12-DEovartis Pharma AG128